IN2014CN00989A - - Google Patents
Info
- Publication number
- IN2014CN00989A IN2014CN00989A IN989CHN2014A IN2014CN00989A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A IN 989CHN2014 A IN989CHN2014 A IN 989CHN2014A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A
- Authority
- IN
- India
- Prior art keywords
- compounds
- treprostinil
- pah
- prodrugs
- covalent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177409 | 2011-08-12 | ||
| EP11195615 | 2011-12-23 | ||
| EP12165508 | 2012-04-25 | ||
| PCT/EP2012/065745 WO2013024052A1 (en) | 2011-08-12 | 2012-08-10 | Carrier-linked treprostinil prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00989A true IN2014CN00989A (de) | 2015-04-10 |
Family
ID=46690494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN989CHN2014 IN2014CN00989A (de) | 2011-08-12 | 2012-08-10 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9561287B2 (de) |
| EP (1) | EP2741781A1 (de) |
| JP (1) | JP6092867B2 (de) |
| KR (1) | KR101997939B1 (de) |
| CN (1) | CN103857413A (de) |
| AU (1) | AU2012296954B2 (de) |
| BR (1) | BR112014003225A2 (de) |
| CA (1) | CA2843883C (de) |
| HK (1) | HK1198359A1 (de) |
| IL (1) | IL230712A (de) |
| IN (1) | IN2014CN00989A (de) |
| MX (1) | MX349950B (de) |
| WO (1) | WO2013024052A1 (de) |
| ZA (1) | ZA201400977B (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103857413A (zh) * | 2011-08-12 | 2014-06-11 | 阿森迪斯药物股份有限公司 | 载体连接的曲罗尼尔前药 |
| WO2013160340A1 (en) * | 2012-04-25 | 2013-10-31 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| JP6290243B2 (ja) | 2012-12-07 | 2018-03-07 | アセンディス ファーマ エー／エス | 担体連結プロスタノイドプロドラッグ |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9371264B2 (en) | 2013-01-11 | 2016-06-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| KR102238501B1 (ko) * | 2013-03-25 | 2021-04-08 | 유나이티드 세러퓨틱스 코오포레이션 | 링커 티올 및 peg화된 형태를 갖는 프로스타시클린 화합물의 제조 방법 |
| EP2991639A4 (de) * | 2013-04-30 | 2016-11-30 | United Therapeutics Corp | Pharmazeutische formulierungen mit kontrollierter freisetzung |
| CN108947843A (zh) | 2013-10-25 | 2018-12-07 | 英斯梅德股份有限公司 | 前列环素化合物、其组合物及使用方法 |
| JO3624B1 (ar) * | 2014-05-08 | 2020-08-27 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| CA2952223C (en) * | 2014-06-13 | 2023-08-01 | United Therapeutics Corporation | Treprostinil formulations |
| EP3169660A1 (de) * | 2014-07-16 | 2017-05-24 | Corsair Pharma, Inc. | Treprostinilderivatverbindungen und verfahren zur verwendung davon |
| CA2967385C (en) | 2014-11-18 | 2023-05-16 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| TWI540121B (zh) | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| EP3226838A1 (de) | 2014-12-03 | 2017-10-11 | Steadymed Ltd. | Konservierungsmittelfreie treprostinilformulierungen sowie verfahren und vorrichtungen zur verwendung damit |
| US9643911B2 (en) * | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| BR112018011008A2 (pt) | 2016-01-08 | 2018-12-04 | Ascendis Pharma Growth Disorders As | agonistas de cnp de liberação controlada com ligação a npr-c baixa |
| IL259658B1 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with reduced side effects |
| PL3400019T3 (pl) | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
| MY195190A (en) | 2016-01-08 | 2023-01-11 | Ascendis Pharma Growth Disorders As | Controlled-Release Cnp Agonists With Increased Nep Stability |
| EP3400022A1 (de) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Cnp-agonisten mit kontrollierter freisetzung mit niedriger anfänglicher npr-b-aktivität |
| MX2018009938A (es) | 2016-03-01 | 2019-03-14 | Ascendis Pharma Bone Diseases As | Profarmacos de hormona paratiroidea (pth). |
| US11896671B2 (en) | 2016-07-13 | 2024-02-13 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| PT3512495T (pt) * | 2016-09-15 | 2023-02-15 | Camurus Ab | Formulações análogas a prostaciclina |
| CA3037442A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
| DK3518961T3 (da) | 2016-09-29 | 2023-04-24 | Ascendis Pharma Bone Diseases As | PTH-forbindelser med lave forhold mellem top og bund |
| CN116059321A (zh) | 2016-09-29 | 2023-05-05 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth的药物组合物 |
| DK3518930T3 (da) | 2016-09-29 | 2023-05-01 | Ascendis Pharma Growth Disorders As | Kombinationsbehandling af en CNP-agonist med kontrolleret frigivelse |
| EP3498283A1 (de) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidische derivate von treprostinil |
| WO2019219896A1 (en) | 2018-05-18 | 2019-11-21 | Ascendis Pharma Bone Diseases A/S | Starting dose of pth conjugates |
| EP3856255A1 (de) | 2018-09-26 | 2021-08-04 | Ascendis Pharma A/S | Behandlung von infektionen |
| CN112770781A (zh) | 2018-09-26 | 2021-05-07 | 阿森迪斯药物股份有限公司 | 新的水凝胶缀合物 |
| WO2020064847A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| EP3906032A1 (de) | 2019-01-04 | 2021-11-10 | Ascendis Pharma Oncology Division A/S | Verzögerte lokale arzneimittelkonzentrationen für angeborene immunagonisten |
| JP2022516308A (ja) | 2019-01-04 | 2022-02-25 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | パターン認識受容体アゴニストのコンジュゲート |
| CA3125488A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| WO2020141225A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma A/S | Minimization of systemic inflammation |
| CN113423384B (zh) | 2019-02-11 | 2024-01-05 | 阿森迪斯药物生长障碍股份有限公司 | Cnp缀合物的干燥药物制剂 |
| CA3129357A1 (en) | 2019-02-11 | 2020-08-20 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of pth conjugates |
| US11458098B2 (en) | 2019-04-29 | 2022-10-04 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
| CA3143279A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 conjugates |
| WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
| WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
| TW202114660A (zh) | 2019-06-21 | 2021-04-16 | 丹麥商阿仙帝斯製藥公司 | 酪胺酸激酶抑制劑結合物 |
| WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| IL294357A (en) | 2020-01-13 | 2022-08-01 | Ascendis Pharma Bone Diseases As | Treatment of hypothyroidism |
| WO2021224169A1 (en) | 2020-05-04 | 2021-11-11 | Ascendis Pharma A/S | Hydrogel irradiation |
| IL298591A (en) * | 2020-06-09 | 2023-01-01 | United Therapeutics Corp | Pomeryl dictopiperidine prodrugs of treprostinil |
| JP2023543265A (ja) | 2020-09-28 | 2023-10-13 | アセンディス ファーマ ボーン ディジージズ エー／エス | 副甲状腺機能低下症を有する患者の身体的及び精神的ウェルビーイングの改善 |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| TW202246206A (zh) * | 2021-03-16 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種曲前列環素衍生物及其用途 |
| WO2023046732A1 (en) | 2021-09-22 | 2023-03-30 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
| WO2023110758A1 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| WO2023110727A2 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Oncology Division A/S | Novel cancer treatments with tlr7/8 agonists |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
| WO2024094673A1 (en) | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| CA2359652A1 (en) * | 1999-03-31 | 2000-10-05 | United Therapeutics Corporation | Novel prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of peripheral vascular disease and pulmonaryhypertension |
| WO2004089280A2 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| EP1696932B1 (de) * | 2003-12-16 | 2009-09-02 | United Therapeutics Corporation | Verwendung von treprostinil zur verbesserung der nierenfunktion |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (de) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel Polymer Prodroge Konjugate |
| EP2491932A3 (de) * | 2007-02-09 | 2012-12-12 | United Therapeutics Corporation | Verwendung von Biomarkern zur Überwachung des Verlaufs der Behandlung einer Lungenerkrankung bei Behandlung mit Treprostinil |
| EP2369005B1 (de) * | 2007-06-21 | 2013-04-03 | Technische Universität München | Biologisch aktive Proteine mit erhöhter in-vivo und/oder in-vitro-Stabilität |
| SI3050576T1 (sl) | 2008-04-29 | 2021-08-31 | Ascendis Pharma Endocrinology Division A/S | Spojine pegiliranega rekombinantnega humanega rastnega hormona |
| WO2010014258A2 (en) | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| EP2331140B1 (de) * | 2008-08-11 | 2018-07-04 | Nektar Therapeutics | Mehrarmige polymer-alkanoat-konjugate |
| EP2341942A1 (de) * | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymerkonjugate aus therapeutischen peptiden |
| CA2744940A1 (en) | 2008-12-10 | 2010-06-17 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
| DK2440228T3 (en) | 2009-06-08 | 2018-12-17 | Amunix Operating Inc | Glucose regulating polypeptides and methods for their preparation and use |
| NZ597960A (en) | 2009-07-31 | 2013-07-26 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| WO2011042450A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
| CN103857413A (zh) * | 2011-08-12 | 2014-06-11 | 阿森迪斯药物股份有限公司 | 载体连接的曲罗尼尔前药 |
-
2012
- 2012-08-10 CN CN201280049725.9A patent/CN103857413A/zh active Pending
- 2012-08-10 US US14/238,437 patent/US9561287B2/en active Active
- 2012-08-10 AU AU2012296954A patent/AU2012296954B2/en not_active Ceased
- 2012-08-10 IN IN989CHN2014 patent/IN2014CN00989A/en unknown
- 2012-08-10 EP EP12748194.3A patent/EP2741781A1/de not_active Withdrawn
- 2012-08-10 BR BR112014003225A patent/BR112014003225A2/pt not_active Application Discontinuation
- 2012-08-10 WO PCT/EP2012/065745 patent/WO2013024052A1/en active Application Filing
- 2012-08-10 CA CA2843883A patent/CA2843883C/en not_active Expired - Fee Related
- 2012-08-10 JP JP2014524413A patent/JP6092867B2/ja not_active Expired - Fee Related
- 2012-08-10 KR KR1020147006343A patent/KR101997939B1/ko active IP Right Grant
- 2012-08-10 MX MX2014001497A patent/MX349950B/es active IP Right Grant
-
2014
- 2014-01-29 IL IL230712A patent/IL230712A/en active IP Right Grant
- 2014-02-10 ZA ZA2014/00977A patent/ZA201400977B/en unknown
- 2014-11-24 HK HK14111870A patent/HK1198359A1/xx unknown
-
2017
- 2017-01-27 US US15/418,180 patent/US10729778B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014003225A2 (pt) | 2017-03-01 |
| KR20140070545A (ko) | 2014-06-10 |
| US10729778B2 (en) | 2020-08-04 |
| KR101997939B1 (ko) | 2019-07-08 |
| AU2012296954B2 (en) | 2016-09-15 |
| CN103857413A (zh) | 2014-06-11 |
| WO2013024052A1 (en) | 2013-02-21 |
| MX349950B (es) | 2017-08-22 |
| CA2843883A1 (en) | 2013-02-21 |
| US20190105400A1 (en) | 2019-04-11 |
| IL230712A0 (en) | 2014-03-31 |
| IL230712A (en) | 2017-08-31 |
| MX2014001497A (es) | 2014-04-25 |
| US9561287B2 (en) | 2017-02-07 |
| JP6092867B2 (ja) | 2017-03-08 |
| AU2012296954A1 (en) | 2014-02-20 |
| HK1198359A1 (en) | 2015-04-10 |
| US20140296150A1 (en) | 2014-10-02 |
| JP2014527050A (ja) | 2014-10-09 |
| ZA201400977B (en) | 2017-11-29 |
| EP2741781A1 (de) | 2014-06-18 |
| CA2843883C (en) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00989A (de) | ||
| PH12017501426A1 (en) | Derivatives of betulin | |
| WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX2015005286A (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| MY187718A (en) | Pharmaceutical formulations | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| IN2012DN02139A (de) | ||
| TN2011000585A1 (en) | Lxr modulators | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| IN2014CN04449A (de) | ||
| WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| IN2013DN02555A (de) | ||
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
| WO2012176163A3 (en) | Compounds for the treatment of cancers associated with human papillomavirus |